Skip to main content

Advertisement

Table 1 (abstract P196). See text for description

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

Patient Group JIA (N=119) ALL (N=22) p
Age, median (IQR) years 13.3 (11.3-15.1) 11.9 (10.2-14.6) 0.18
Gender, girls: boys 81 : 38 9 : 13 -
MTXO: MTXSC, n 45 : 74 22 : 0 -
MTX dose, median (IQR) mg/m2/week 9.7 (9.0-10.9) 14.7 (10.4-20.0) 0.0002
 MTXintol : MTXtol 9.6 (8.6-11.0) : 10.1 (9.4-10.9)a 16.3 (14.7-18.4): 13.3 (9.0-21.0)b a0.22 ; b0.55
E-MTX-PG, mean (95% CI) nmol/ mmol Hb 5.3 (4.9-5.6) 6.5 (5.5-7.6) 0.028
 MTXintol: MTXtol 5.4 (5.0-5.9) : 5.0 (4.5-5.5)a 7.6 (4.5-10.8) : 6.3 (5.0-7.5)b a0.21; b0.31
MTX treatment duration, median (IQR) days 336 (141-766) 114 (71-254) 0.0003
 MTXintol: MTXtol 370 (143-766) : 262 (141-629)a 300 (191-354) : 97 (64-197)b a0.38 ; b0.033